Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conatumumab + panitumumab
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Conatumumab + panitumumab is a combination therapy used in the treatment of metastatic colorectal cancer. Conatumumab is a monoclonal antibody that targets death receptor 5 (DR5) and mediates apoptosis of tumor cells with low toxicity to normal cells. Panitumumab is a fully humanized IgG2 monoclonal antibody that binds competitively to the extracellular domain of epidermal growth factor receptor (EGFR), preventing its activation and halting the cascade of intracellular signals dependent on this receptor. The combination has been studied in clinical trials for patients with metastatic colorectal cancer.
- Brand names
- Vectibix
- Other names
- conatumumab and panitumumab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TNFRSF10B (DR5)
Beyond the preview
Go deeper on conatumumab + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conatumumab + panitumumab.